New malaria tools are emerging, but access for the people who need them most is slowed by fragmented markets, complex regulations, and limited visibility on supply and demand. To address these challenges, Unitaid, in collaboration with the RBM Partnership to End Malaria and with funding from the Gates Foundation, has launched a new initiative aimed at increasing transparency across malaria product introduction and accelerating market entry. The initiative will make data on product pipelines and market dynamics more accessible through an online platform hosted on the RBM dashboard. By improving data accessibility, the initiative seeks to identify roadblocks earlier, enable timely action by countries and partners, and support evidence-based decisions to bring malaria innovations to communities faster.
The project will initially focus on two priority areas funded by Unitaid: antimalarial treatments needed for multiple first-line therapy strategies to counter drug resistance, and spatial emanators, innovative vector control tools that complement insecticide-treated nets and indoor residual spraying. According to Dr. Philippe Duneton, Executive Director at Unitaid, improving visibility and coordination among partners is key to accelerating access to new health tools, and this initiative will provide transparent data to support faster, better-informed decisions.
Malaria continues to be a major global health challenge, claiming the life of one person every minute. While significant progress was made earlier this century, gains have stalled due in part to increasing drug and insecticide resistance. Continuous innovation is essential to ensure malaria tools remain effective against evolving biological threats. The initiative aligns with the Big Push to End Malaria, a global effort to accelerate malaria elimination by improving coordination among countries, donors, and partners. Integrating the transparency platform into the RBM dashboard provides a shared view of product readiness and market dynamics, helping partners plan more effectively, strengthen accountability, and optimize limited global health resources.
Dr. Michael Adekunle Charles, CEO of the RBM Partnership to End Malaria, emphasized that reliable and accessible data is critical for decision-making and resource optimization. The initiative will support ongoing innovation to counter antimalarial drug resistance while strengthening vector control efforts, enabling partners to monitor the introduction of new tools and use data to inform their malaria response strategies. The Big Push to End Malaria sets actionable priorities for the next five years, operationalizing strategies such as the Yaoundé Declaration and the Lusaka Agenda, and includes a robust accountability framework to maximize impact and ensure measurable results in reducing the global malaria burden.
